Last reviewed 2026-05-29 · How we verify

VaxigripTetra inj.

Sanofi · Phase 2 active Biologic ✓ Verified May 2026

VaxigripTetra inj. is a Biologic drug developed by Sanofi. It is currently in Phase 2 development. Also known as: Quadrivalent influenza vaccine (split-virion, inactivated) - QIV.

VaxigripTetra inj. is a vaccine used to prevent influenza in individuals aged 3 years and above. It is a quadrivalent influenza vaccine, meaning it protects against four different strains of the influenza virus.

Likelihood of approval

18.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Sanofi is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VaxigripTetra inj.
Also known as	Quadrivalent influenza vaccine (split-virion, inactivated) - QIV
Sponsor	Sanofi
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VaxigripTetra inj. CI brief — competitive landscape report
VaxigripTetra inj. updates RSS · CI watch RSS
Sanofi portfolio CI

Frequently asked questions about VaxigripTetra inj.

What is VaxigripTetra inj.?

VaxigripTetra inj. is a Biologic drug developed by Sanofi.

Who makes VaxigripTetra inj.?

VaxigripTetra inj. is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is VaxigripTetra inj. also known as anything else?

VaxigripTetra inj. is also known as Quadrivalent influenza vaccine (split-virion, inactivated) - QIV.

What development phase is VaxigripTetra inj. in?

VaxigripTetra inj. is in Phase 2.

Manufacturer: Sanofi — full pipeline
Also known as: Quadrivalent influenza vaccine (split-virion, inactivated) - QIV

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing